Clonal Hematopoiesis (CHIP): A New Frontier in Heart Disease Risk and Treatment
Researchers at the Centro Nacional de Investigaciones Cardiovasculares (CNIC) have identified clonal hematopoiesis as a new risk factor for atherosclerosis and cardiovascular disease. Clonal hematopoiesis, caused by acquired mutations in blood stem cells, was found to contribute to the development of atherosclerosis rather than being a consequence of it. This discovery adds to the list of established cardiovascular risk factors and opens up new possibilities for prevention strategies. The study, published in Nature Medicine, used data from the PESA-CNIC-Santander study to demonstrate that individuals with mutations linked to clonal hematopoiesis at the start of the study were more likely to develop atherosclerosis in subsequent years.
In a related study published in the European Heart Journal, the CNIC team, in collaboration with researchers from the Broad Institute, found that the ancient anti-inflammatory drug colchicine could potentially mitigate the cardiovascular risks associated with mutations in the TET2 gene, which is commonly linked to clonal hematopoiesis. Animal studies showed that colchicine administration slowed the development of atherosclerosis in subjects with TET2 mutations. Additionally, human data indicated that individuals with TET2 mutations who had been treated with colchicine for other conditions had a lower risk of myocardial infarction. These findings lay the groundwork for potential personalized medicine strategies to address the cardiovascular risks associated with clonal hematopoiesis, particularly for carriers of TET2 mutations.
